The product is a bio-equivalent generic version of Amoxil (Amoxicillin) tablets, capsules, and oral suspension.
Officially launched on September 17 in the US, Amoxicillin tablets (500 mg and 875 mg), capsules (250 mg and 500 mg), and oral suspension (125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, and 400 mg/5 ml) are approved by the United States Food and Drug Administration (US FDA).
In a press release, the Hyderabad-based pharma major said the Amoxil brand and generic tablets (875 mg) has US sales of approximately $22.2 million, capsules ($67.2 m), and oral suspension ($89.5 m), for the 12 months ended June 30, 2012 quoting IMS Health.
Dr. Reddy’s Amoxicillin tablets will be available in bottle counts of 20 and 100; Amoxicillin capsules in bottle counts of 100 and 500 and oral suspension in 200 mg/5 ml and 400 mg/5 ml, in three counts of 50 ml, 75 ml, and 100 ml.
Amoxicillin oral suspension in 125 mg/5 ml and 250 mg/5 ml will be available in bottle sizes of 80 ml, 100 ml, and 150 ml.
